Patent review: therapeutic applications for antisense oligonucleotides 1999-2000.
Over 200 patents disclosing antisense sequences have been published in the last year. 30 Of these, in which a therapeutic application is claimed, have been reviewed in this article. We have classified these under the headings of antibacterial, antiviral, inflammation, cardiovascular, apoptosis and anticancer. Although not exhaustive or covering all diseases, major areas of antisense research have been addressed.
CRC Centre for Cancer Therapeutics, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK. rosanne@icr.ac.uk
R M
RM
Orr
C F
CF
O'Neill
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D001419:Bacteria / Q000187:drug effects / Q000254:growth & development; D002318:Cardiovascular Diseases / Q000188:drug therapy; D002455:Cell Division / Q000187:drug effects; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*; D010330:Patents as Topic; D015398:Signal Transduction / Q000187:drug effects
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D016376:Oligonucleotides, Antisense